These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33453443)

  • 1. Mineral and organic matrix composition at bone forming surfaces in postmenopausal women with osteoporosis treated with either teriparatide or zoledronic acid.
    Paschalis EP; Dempster DW; Gamsjaeger S; Rokidi S; Hassler N; Brozek W; Chan-Diehl FW; Klaushofer K; Taylor KA
    Bone; 2021 Apr; 145():115848. PubMed ID: 33453443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.
    Hofstetter B; Gamsjaeger S; Varga F; Dobnig H; Stepan JJ; Petto H; Pavo I; Klaushofer K; Paschalis EP
    Osteoporos Int; 2014 Dec; 25(12):2709-19. PubMed ID: 25037600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of postmenopausal osteoporosis patients with teriparatide for 24 months reverts forming bone quality indices to premenopausal healthy control values.
    Paschalis EP; Gamsjaeger S; Klaushofer K; Shane E; Cohen A; Stepan J; Pavo I; Eriksen EF; Taylor KA; Dempster DW
    Bone; 2022 Sep; 162():116478. PubMed ID: 35779845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Effects of Teriparatide and Zoledronic Acid on Bone Mineralization Density Distribution at 6 and 24 Months in the SHOTZ Study.
    Dempster DW; Roschger P; Misof BM; Zhou H; Paschalis EP; Alam J; Ruff VA; Klaushofer K; Taylor KA
    J Bone Miner Res; 2016 Aug; 31(8):1527-35. PubMed ID: 26931279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial.
    Dempster DW; Zhou H; Recker RR; Brown JP; Bolognese MA; Recknor CP; Kendler DL; Lewiecki EM; Hanley DA; Rao SD; Miller PD; Woodson GC; Lindsay R; Binkley N; Alam J; Ruff VA; Gallagher ER; Taylor KA
    J Bone Miner Res; 2016 Jul; 31(7):1429-39. PubMed ID: 26841258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Gamsjaeger S; Buchinger B; Zoehrer R; Phipps R; Klaushofer K; Paschalis EP
    Bone; 2011 Dec; 49(6):1160-5. PubMed ID: 21893225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid.
    Gamsjaeger S; Buchinger B; Zwettler E; Recker R; Black D; Gasser JA; Eriksen EF; Klaushofer K; Paschalis EP
    J Bone Miner Res; 2011 Jan; 26(1):12-8. PubMed ID: 20645415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 3 years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients.
    Gamsjaeger S; Hofstetter B; Zwettler E; Recker R; Gasser JA; Eriksen EF; Klaushofer K; Paschalis EP
    Osteoporos Int; 2013 Jan; 24(1):339-47. PubMed ID: 23229465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.
    Dempster DW; Zhou H; Recker RR; Brown JP; Bolognese MA; Recknor CP; Kendler DL; Lewiecki EM; Hanley DA; Rao DS; Miller PD; Woodson GC; Lindsay R; Binkley N; Wan X; Ruff VA; Janos B; Taylor KA
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2799-808. PubMed ID: 22701017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis.
    Ma YL; Marin F; Stepan J; Ish-Shalom S; Möricke R; Hawkins F; Kapetanos G; de la Peña MP; Kekow J; Martínez G; Malouf J; Zeng QQ; Wan X; Recker RR
    Bone; 2011 May; 48(5):972-8. PubMed ID: 21262402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early effects of zoledronic acid and teriparatide on bone microarchitecture, remodeling and collagen crosslinks: comparison between iliac crest and lumbar vertebra in ewes.
    Portero-Muzy NR; Chavassieux PM; Bouxsein ML; Gineyts E; Garnero P; Chapurlat RD
    Bone; 2012 Oct; 51(4):714-9. PubMed ID: 22796591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial.
    Paschalis EP; Glass EV; Donley DW; Eriksen EF
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4644-9. PubMed ID: 15914535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone Mineral and Organic Properties in Postmenopausal Women Treated With Denosumab for Up to 10 years.
    Farlay D; Rizzo S; Dempster DW; Huang S; Chines A; Brown JP; Boivin G
    J Bone Miner Res; 2022 May; 37(5):856-864. PubMed ID: 35249242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal Effects of Teriparatide or Zoledronic Acid on Bone Modeling- and Remodeling-Based Formation in the SHOTZ Study.
    Dempster DW; Zhou H; Ruff VA; Melby TE; Alam J; Taylor KA
    J Bone Miner Res; 2018 Apr; 33(4):627-633. PubMed ID: 29194749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of alendronate and risedronate on bone material properties in actively forming trabecular bone surfaces.
    Hofstetter B; Gamsjaeger S; Phipps RJ; Recker RR; Ebetino FH; Klaushofer K; Paschalis EP
    J Bone Miner Res; 2012 May; 27(5):995-1003. PubMed ID: 22336962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
    Durchschlag E; Paschalis EP; Zoehrer R; Roschger P; Fratzl P; Recker R; Phipps R; Klaushofer K
    J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teriparatide Treatment Increases Mineral Content and Volume in Cortical and Trabecular Bone of Iliac Crest: A Comparison of Infrared Imaging With X-Ray-Based Bone Assessment Techniques.
    Paschalis EP; Krege JH; Gamsjaeger S; Eriksen EF; Burr DB; Disch DP; Stepan JJ; Fahrleitner-Pammer A; Klaushofer K; Marin F; Pavo I
    J Bone Miner Res; 2018 Dec; 33(12):2230-2235. PubMed ID: 30102789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
    Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
    J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality.
    Paschalis EP; Gamsjaeger S; Hassler N; Fahrleitner-Pammer A; Dobnig H; Stepan JJ; Pavo I; Eriksen EF; Klaushofer K
    Bone; 2017 Feb; 95():41-46. PubMed ID: 27826025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.